<DOC>
	<DOCNO>NCT02186171</DOCNO>
	<brief_summary>This phase 3 multicenter study compare efficacy safety Romosozumab ( AMG 785 ) placebo men osteoporosis .</brief_summary>
	<brief_title>A Double-blind Study Compare Safety Efficacy Romosozumab ( AMG 785 ) Versus Placebo Men With Osteoporosis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study approximately 225 men osteoporosis . The study design evaluate treatment romosozumab month 12 month compare placebo effective increase BMD lumbar spine . Additionally , study assess effect treatment romosozumab 12 month compare placebo BMD femoral neck total hip .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Must ambulatory male subject ≥ 55 year ≤ 90 year age Must BMD T score ≤ 2.50 spine hip , BMD T score ≤ 1.50 spine hip history fragility nonvertebral fracture vertebral facture . A BMD T score ≤ 3.50 hip , History hip fracture Severe metabolic bone diseases Significant laboratory abnormality Recent treatment agent affect bone metabolism</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Osteoporosis men</keyword>
</DOC>